Cancer statistics: Breast cancer in situ

Area of Science:

• Oncology
• Public Health
• Epidemiology

Background:

• Breast carcinoma in situ, including ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), represents a significant proportion of new breast cancer diagnoses.
• Despite their prevalence, clinical significance and optimal management strategies for in situ breast cancers remain areas of uncertainty for patients and clinicians.

Purpose of the Study:

• To provide comprehensive information on the occurrence and treatment patterns of DCIS and LCIS in the United States.
• To offer an overview of detection, risk factors, prevention, and to identify research needs and initiatives for in situ breast cancers.

Main Methods:

• Utilized data from the North American Association of Central Cancer Registries.
• Analyzed data from the 13 oldest Surveillance, Epidemiology, and End Results (SEER) registries.
• Compiled information on occurrence, treatment, risk factors, and prevention.

Main Results:

• An estimated 60,290 new cases of breast carcinoma in situ were expected in 2015.
• Approximately 1 in 33 women are diagnosed with in situ breast cancer in their lifetime.
• The article details patterns for the two major subtypes: DCIS and LCIS.

Conclusions:

• In situ breast cancers are common, necessitating a clear understanding of their clinical significance and treatment.
• Further research is needed to address uncertainties in detection, treatment, risk factors, and prevention strategies.
• This review serves as a foundational resource for clinicians and patients regarding in situ breast cancer.